NCT04662151CompletedPhase 1
A Phase 1b, Randomized, Blinded, Dose-Determined Study Evaluating the Safety and Tolerability Profile of Intervention With AT-100 (rhSP-D) in Preterm Neonates at High Risk for the Development of Bronchopulmonary Dysplasia (BPD)
Airway Therapeutics, Inc.20 sites in 2 countries37 target enrollmentStarted: September 1, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Completed
- Sponsor
- Airway Therapeutics, Inc.
- Enrollment
- 37
- Locations
- 20
- Primary Endpoint
- Incidence of BPD or death
Study Overview
Brief Summary
The purpose of this study is to determine if an investigational drug, AT-100, can reduce the occurrence of Bronchopulmonary Dysplasia (BPD) in babies born premature, as compared to babies born premature who receive an air-sham alone.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Single (Participant)
Eligibility Criteria
- Ages
- 0 Minutes to 96 Hours (Child)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Weight at time of birth < 400 g or > 1,800 g.
- •Major apparent congenital abnormalities impacting cardio and pulmonary function.
- •Active DNR (Do Not Resuscitate) order in place.
- •Known pulmonary air leaks (e.g. pneumothorax and pneumomediastinum) at the time of AT-100 or air-sham administration.
- •History of allergy or sensitivity to any surfactant or any component of the Investigational Product (AT-100).
- •AT-100 or air-sham dosing was set to occur before Data Safety Monitoring Committee recommendation to proceed to the next dose-escalation cohort.
- •Use of minimally invasive surfactant techniques (e.g., LISA, MIST) or INSURE or if, in the opinion of the care team, the infant is very likely too be extubated shortly after receiving Curosurf®.
- •a. Subjects extubated and re-intubated after their Curosurf® dose(s) are eligible, so long as the subject meets Inclusion #
- •Birth mother:
- •Has known active Hepatitis B, C, or E diagnosis.
- •Has a known illness or exposure that, in the judgement of the Investigator, is serious enough to induce an immune deficiency such as Human Immunodeficiency Virus (HIV) and/or is receiving chemotherapy.
- •Has known active Sexually Transmitted Infection (STI).
- •Has known Cytomegalovirus (CMV) active infection.
- •Has known history or evidence of alcohol or drug abuse, wit the exception of marijuana/marijuana-based products/THC, based on a positive maternal or infant drug screen as evidenced by the institution's standard-of-care practice.
- •Concurrent enrollment in an investigational drug, device, or treatment modulation trial that utilizes treatments outside of standard-of-care.
- •Any condition or situation which, in the Investigator's judgement, puts the mother or the neonate at significant risk, could confound the trial results, or may interfere significantly with the mother's or neonate's participation in the trial.
- •Symptomatic and confirmed COVID-19 infection of the mother around the time of birth.
Outcomes
Primary Outcomes
Incidence of BPD or death
Time Frame: Week 36 PMA
Number of participants with treatment-related adverse events
Time Frame: Adverse events will be followed up to Day 28 of life
Incidence and severity of adverse events between the two treatment groups will be compared
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (20)
Loading locations...
Similar Trials
Completed
Phase 2
Safety and Efficacy of ART-123 in Subjects With Sepsis and Disseminated Intravascular CoagulationSepsisDisseminated Intravascular CoagulationNCT00487656Artisan Pharma, Inc.750
Terminated
Phase 2
A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.Vaso-occlusive CrisisSickle Cell DiseaseNCT01522196Anthera Pharmaceuticals2
Completed
Phase 2
Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)Minimal Change DiseaseFocal Segmental GlomerulosclerosisNephrotic SyndromeNCT02592798Bristol-Myers Squibb36
Terminated
Phase 2
AT1001 for the Treatment of COVID-19 Related MIS-CCovid19Multisystem Inflammatory Syndrome in ChildrenNCT05022303Massachusetts General Hospital12
Terminated
Phase 1
A Clinical Safety Study on AT-100 in Treating Adults With Severe COVID-19 Infection or Severed Community Acquired PneumoniaUndefinedCOVID-19NCT04659122Airway Therapeutics, Inc.5